GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC –2023 Gilead Asia Pacific Rainbow Grant Funding Will Support 40 Projects In 2024-2025 To Reduce HIV Stigma And Improve Equity Across Asia Pacific – – Since 2018, The Gilead Asia Pacific R.
-Gilead Sciences Celebrates the Fifth Anniversary Milestone of the Asia Pacific Rainbow Grant, with MoreThan US$4.5 Million Awarded to Organizations across the Asia Pacific Region to Date - - Grant Program in 2023 Invites HIV-Focused Community-Based Organizations to Apply for Funding for Innovative Projects Centered on Theme 'Reducing Stigma & Improving Equity' - SINGAPORE, May 1, 2023 /PRNewswire/ Gilead Sciences, Inc. today announced the launch of its 2023 Asia Pacific Rainbow Grant, marking the fifth anniversary milestone of a regional program which supports community projects to address HIV-related needs in Asia Pacific. Non-profit organizations are invited to submit their applications for 2023 funding online through the Gilead Grant portalstarting today. The submission deadline ends on 28 July 2023, 11:59pm GMT+8. In Asia Pacific, there are still about six million people living with HIV in the region[1] who face social and cultural stigma and punitive laws that preve
- Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemic - Top factor impacting usage of telehealth services for PLHIV is data privacy (43%), while lack of personal contact is the primary concern for IARs (47%) - Around 1 in 3 respondents chose telehealth services provided by healthcare providers (HCPs) as the most trustworthy source for HIV prevention and care information SINGAPORE, Nov. 28, 2022 /PRNewswire/ As the COVID-19 pandemic continues to disrupt the access and delivery of essential care worldwide, Gilead Sciences today announced findings from a survey conducted to examine changes in the motivations and use of telehealth services for people living with HIV (PLHIV) and individuals at-risk (IARs) in the Asia Pacific. The regional survey results were based on responses from 1,531 respondents, co
In the recently published PatientView report, Gilead is ranked number one in all corporate reputation indicators by hepatitis patient groups globally Gilead also ranks first among peers in Asia by patient groups in this region HONG KONG, Sept. 15, 2022 /PRNewswire/ Gilead Sciences, Inc. ranks first among peers for overall corporate reputation, according to 300 Asian patient groups and 111 hepatitis patient groups in the 2021 PatientView Corporate Reputation of Pharma survey. This recognition is testament to Gilead's strong focus on patient centricity and deep commitment to working with patient groups to enhance the quality of care for communities across the world. "This is a remarkable achievement for Gilead and it is heartening to know that patient groups rate us highly in all areas - seeing us as the partner of choice," said Dustin Haines, Vice President & General Manager, Asia 5, Gilead Sciences. "We put patients at the heart of everything we do, and